Bacterial proteins, enzymes, and cell membranes

Bacterial proteins, enzymes, and cell membranes" is a collective reference to the fundamental structural and functional molecules in bacteria, encompassing a wide array of **membrane proteins and complex lipid bilayers**, **diverse enzymes** (such as those involved in cell wall synthesis, metabolism, and antibiotic resistance), and the **membrane itself** as a physical and physiological barrier. As a group, these entities are essential for bacterial viability, proliferation, and pathogenicity. However, this entry is not a proper scientific target but a composite of many unrelated targets, each with specific properties, biological functions, and druggability profiles. For instance, therapeutic agents can be designed to inhibit individual bacterial enzymes (such as β-lactamases or penicillin-binding proteins), disrupt membrane structure (with lipopeptides or peptides), or target specific membrane proteins (such as transporters, pore-formers, or surface antigens for antibody therapy). The broad scope of "bacterial proteins, enzymes, and cell membranes" makes it unfit for direct scientific, clinical, or pharmacological use as a single molecular target. Instead, each component (e.g., “Penicillin-binding protein 2a,” “FtsZ,” “Class A β-lactamase,” “Peptidoglycan synthase,” “Bacterial ATP synthase,” or “Lipid II precursor”) should be identified and characterized individually for meaningful therapeutic targeting[1][3][4][5][9].

Inhibition of cell wall biosynthesis (e.g., β-lactams, glycopeptides, targeting penicillin-binding proteins or peptidoglycan synthases); Disruption of membrane integrity (e.g., polymyxins, daptomycin, antimicrobial peptides); Inhibition of protein synthesis (targeting ribosomal subunits); Inhibition of DNA/RNA synthesis (e.g., fluoroquinolones); Enzyme inhibition (e.g., β-lactamase inhibition); Neutralization of toxins (therapeutic mAbs); Interference with metabolic/energetic enzymes (e.g., ATP synthase inhibitor, diarylquinoline TMC207)